{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["HCV NS3/4A protease", "RECAP analyses", "RECAP synthesis", "inhibitors", "molecular docking"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36770965", "DateCompleted": {"Year": "2023", "Month": "02", "Day": "14"}, "DateRevised": {"Year": "2023", "Month": "02", "Day": "14"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "01", "Day": "29"}], "Language": ["eng"], "ELocationID": ["1300", "10.3390/molecules28031300"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "28", "Issue": "3", "PubDate": {"Year": "2023", "Month": "Jan", "Day": "29"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "A Novel Approach to Develop New and Potent Inhibitors for the Simultaneous Inhibition of Protease and Helicase Activities of HCV NS3/4A Protease: A Computational Approach.", "Abstract": {"AbstractText": ["Infection of hepatitis C (HCV) is a major threat to human health throughout the world. The current therapy program suffers from restricted efficiency and low tolerance, and there is serious demand frr novel medication. NS3/4A protease is observed to be very effective target for the treatment of HCV. A data set of the already reported HCV NS3/4A protease inhibitors was first docked into the NS3/4A protease (PDB ID: 4A92A) active sites of both protease and helicase sites for calculating the docking score, binding affinity, binding mode, and solvation energy. Then the data set of these reported inhibitors was used in a computer-based program \"RECAP Analyses\" implemented in MOE to fragment every molecule in the subset according to simple retrosynthetic analysis rules. The RECAP analysis fragments were then used in another computer-based program \"RECAP Synthesis\" to randomly recombine and generate synthetically reasonable novel chemical structures. The novel chemical structures thus produced were then docked against HCV NS3/4A. After a thorough validation of all undertaken steps, based on Lipinski's rule of five, docking score, binding affinity, solvation energy, and Van der Waal's interactions with HCV NS3/4A, 12 novel chemical structures were identified as inhibitors of HCV NS3/4A. The novel structures thus designed are hoped to play a key role in the development of new effective inhibitors of HCV."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Computational Medicinal Chemistry Laboratory, Department of Biochemistry, Abdul Wali Khan University Mardan, Mardan 23200, Pakistan."}], "LastName": "Riaz", "ForeName": "Muhammad", "Initials": "M"}, {"Identifier": ["0000-0002-7261-3645"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Biological Science, University of California, Irvine, CA 92697, USA."}], "LastName": "Rehman", "ForeName": "Ashfaq Ur", "Initials": "AU"}, {"Identifier": ["0000-0001-6115-9689"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural and Medical Sciences Research Center, University of Nizwa, Birkat Al Mauz, P.O. Box 33, Nizwa 616, Oman."}], "LastName": "Waqas", "ForeName": "Muhammad", "Initials": "M"}, {"Identifier": ["0000-0001-8734-2588"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Substance Abuse and Toxicology Research Center, Jazan University, P.O. Box 114, Jazan 45142, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Medicinal and Aromatic Plants and Traditional Medicine Research Institute, National Center for Research, Khartoum P.O. Box 2404, Sudan."}], "LastName": "Khalid", "ForeName": "Asaad", "Initials": "A"}, {"Identifier": ["0000-0003-4770-9319"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia."}], "LastName": "Abdalla", "ForeName": "Ashraf N", "Initials": "AN"}, {"Identifier": ["0000-0002-0309-1230"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Center for Medical Genetics and Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China."}], "LastName": "Mahmood", "ForeName": "Arif", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Central Laboratory, SSL, Central Hospital of Dongguan City, Affiliated Dongguan Shilong People's Hospital of Southern Medical University, Dongguan 523000, China."}], "LastName": "Hu", "ForeName": "Junjian", "Initials": "J"}, {"Identifier": ["0000-0002-3415-9277"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Computational Medicinal Chemistry Laboratory, Department of Biochemistry, Abdul Wali Khan University Mardan, Mardan 23200, Pakistan."}], "LastName": "Wadood", "ForeName": "Abdul", "Initials": "A"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "EC 3.4.-", "NameOfSubstance": "Endopeptidases"}, {"RegistryNumber": "0", "NameOfSubstance": "Viral Nonstructural Proteins"}, {"RegistryNumber": "0", "NameOfSubstance": "Protease Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Antiviral Agents"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Molecular Dynamics Simulation"}, {"QualifierName": ["metabolism"], "DescriptorName": "Endopeptidases"}, {"QualifierName": [], "DescriptorName": "Hepacivirus"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Hepatitis C"}, {"QualifierName": [], "DescriptorName": "Catalytic Domain"}, {"QualifierName": ["metabolism"], "DescriptorName": "Viral Nonstructural Proteins"}, {"QualifierName": ["chemistry"], "DescriptorName": "Protease Inhibitors"}, {"QualifierName": ["chemistry"], "DescriptorName": "Antiviral Agents"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Sch\u00fctte K., Balbisi F., Malfertheiner P. Prevention of hepatocellular carcinoma. Gastrointest. Tumors. 2016;3:37\u201343. doi: 10.1159/000446680.", "ArticleIdList": ["10.1159/000446680", "PMC5040884", "27722155"]}, {"Citation": "Fattah M.A., Al-Marhabi O., Matrafi M., Babaseel M., Asmari M., Eletlany S. Sero-prevalence of Hepatitis B virus infections among blood banking donors in Makkah city, Saudi Arabia: An institutional-based cross-sectional study. J. Umm Al-Qura Univ. Med. Sci. 2020;6:2."}, {"Citation": "Rabban A.A., Bakhreba M.A., Nasa M., Natto Z.S., Al-Mutair A., Alhumaid S., Aljeldah M., Garout M., Alfouzan W.A., Alshahrani F.S., et al. Suspected adenovirus causing an emerging hepatitis among children below 10 years: A review. Pathogens. 2022;11:712. doi: 10.3390/pathogens11070712.", "ArticleIdList": ["10.3390/pathogens11070712", "PMC9317240", "35889958"]}, {"Citation": "Houghton M. HCV: The Journey from Discovery to a Cure. Springer; Berlin/Heidelberg, Germany: 2019. The discovery of the hepatitis C virus; pp. 19\u201327."}, {"Citation": "Ismail N.S.M., Hattori M. Molecular modeling based approach, synthesis and in vitro assay to new indole inhibitors of hepatitis C NS3/4A serine protease. Bioorgan. Med. Chem. 2011;19:374\u2013383. doi: 10.1016/j.bmc.2010.11.017.", "ArticleIdList": ["10.1016/j.bmc.2010.11.017", "21138791"]}, {"Citation": "Hepatitis C General Information\u2014CDC.  [(accessed on 16 January 2013)].  Available online:  http://wwwcdcgov/hepatitis/HCV/PDFs/HepCGeneralFactSheet.pdf."}, {"Citation": "Akhtar S., Nasir J.A., Hinde A. The prevalence of hepatitis C virus infection in \u03b2-thalassemia patients in Pakistan: A systematic review and meta-analysis. BMC Public Health. 2020;20:587. doi: 10.1186/s12889-020-8414-5.", "ArticleIdList": ["10.1186/s12889-020-8414-5", "PMC7191777", "32349737"]}, {"Citation": "Colvin H.M., Mitchell A.E. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitits B and C. Institute of Medicine Committee on the Prevention and Control of Viral Hepatitis Infections, National Academies Press; Washington, DC, USA: 2010.", "ArticleIdList": ["25032367"]}, {"Citation": "Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis management and treatment of hepatitis C: An update. J. Hepatol. 2009;49:1335. doi: 10.1002/hep.22759.", "ArticleIdList": ["10.1002/hep.22759", "PMC7477893", "19330875"]}, {"Citation": "Cacoub P., Bourli\u00e8re M., L\u00fcbbe J., Dupin N., Buggisch P., Dusheiko G., Roujeau J.C. Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals. J. Hepatol. 2012;56:455\u2013463. doi: 10.1016/j.jhep.2011.08.006.", "ArticleIdList": ["10.1016/j.jhep.2011.08.006", "21884670"]}, {"Citation": "Manns M.P., McHutchison J.G., Gordon S.C., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 2001;358:958. doi: 10.1016/S0140-6736(01)06102-5.", "ArticleIdList": ["10.1016/S0140-6736(01)06102-5", "11583749"]}, {"Citation": "Liu C.H., Liu C.J., Huang C.F., Lin J.W., Dai C.Y., Liang C.C., Kao J.H. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial. Gut. 2015;64:303. doi: 10.1136/gutjnl-2014-307080.", "ArticleIdList": ["10.1136/gutjnl-2014-307080", "24747867"]}, {"Citation": "Flisiak R., Parfieniuk A. Investigational drugs for hepatitis C. Expert. Opin. Investig. Drugs. 2010;19:63\u201375. doi: 10.1517/13543780903431034.", "ArticleIdList": ["10.1517/13543780903431034", "20001555"]}, {"Citation": "Kwong A.D., McNair L., Jacobson I., George S. Recent progress in the development of selected hepatitis C virus NS3 4A protease and NS5B polymerase inhibitors. Curr. Opin. Pharmacol. 2008;8:522. doi: 10.1016/j.coph.2008.09.007.", "ArticleIdList": ["10.1016/j.coph.2008.09.007", "18835365"]}, {"Citation": "Lindenbach B.D., Rice C.M. Field\u2019s Virology. Lippincott Williams and Wilkins; Philadelphia, PA, USA: 2001. Flaviviridae: The viruses and their replication."}, {"Citation": "Lindenbach B.D., Rice C.M. Unraveling hepatitis C virus replication: From genometo function. Nature. 2005;436:933. doi: 10.1038/nature04077.", "ArticleIdList": ["10.1038/nature04077", "16107832"]}, {"Citation": "Assenberg R., Mastrangelo E., Walter T.S., Verma A., Milani M., Owens R.J., Stuart D.I., Grimes J.M., Mancini E.J. Crystal structure of a novel conformational state of the flavivirus NS3 protein: Implications for polyprotein processing and viral replication. J. Virol. 2009;83:12895\u201312906. doi: 10.1128/JVI.00942-09.", "ArticleIdList": ["10.1128/JVI.00942-09", "PMC2786852", "19793813"]}, {"Citation": "Zaj\u0105c M., Muszalska I., Sobczak A., Dadej A., Tomczak S., Jeli\u0144ska A. Hepatitis C\u2014New drugs and treatment prospects. Eur. J. Med. Chem. 2019;165:225\u2013249. doi: 10.1016/j.ejmech.2019.01.025.", "ArticleIdList": ["10.1016/j.ejmech.2019.01.025", "30685524"]}, {"Citation": "Brass V., Berke J.M., Montserret R., Blum H.E., Penin F., Moradpour D. Structural determinants for membrane association and dynamic organization of the Hepatitis C Virus NS3-4A complex. Proc. Natl. Acad. Sci. USA. 2008;105:14545\u201314550. doi: 10.1073/pnas.0807298105.", "ArticleIdList": ["10.1073/pnas.0807298105", "PMC2567209", "18799730"]}, {"Citation": "Schiering N., Arcy A.D., Villard F., Simi\u0107 O., Kamke M., Monnet G., Hassiepen U., Svergun D.I., Pulfer R., Eder J., et al. A macrocyclic HCVNS3/4A protease inhibitor interacts with protease and helicase residues in the complex with its full-length target. Proc. Natl. Acad. Sci. USA. 2011;108:21052. doi: 10.1073/pnas.1110534108.", "ArticleIdList": ["10.1073/pnas.1110534108", "PMC3248494", "22160684"]}, {"Citation": "Huang M., Phadke A., Agarwal A. Proteases in Gastrointestinal Tissue. Springer; Berlin/Heidelberg, Germany: 2006. Hepatitis C viral proteases and inhibitors."}, {"Citation": "Bartenschlager R., Ahlborn-Laake L., Mous J., Jacoben H. Kinetic and structural analysis of hepatitis C virus polyprotein processing. J. Virol. 1994;68:5045. doi: 10.1128/jvi.68.8.5045-5055.1994.", "ArticleIdList": ["10.1128/jvi.68.8.5045-5055.1994", "PMC236447", "8035505"]}, {"Citation": "Chen K.X., Njoroge F.G. A review of HCV protease inhibitors. Curr. Opin. Investig. Drugs. 2009;10:821.", "ArticleIdList": ["19649927"]}, {"Citation": "Reiser M., Timm J. Serine protease inhibitors as anti-hepatitis C virus agents. Expert Rev. Anti-Infect. Ther. 2009;7:537. doi: 10.1586/eri.09.30.", "ArticleIdList": ["10.1586/eri.09.30", "19485794"]}, {"Citation": "Melnikova I. Hepatitis C\u2014Pipeline update. Nat. Rev. Drug. Discov. 2011;10:93. doi: 10.1038/nrd3361.", "ArticleIdList": ["10.1038/nrd3361", "21283098"]}, {"Citation": "Rong L., Dahari H., Ribeiro R.M., Perelson A. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci. Transl. Med. 2010;2:30\u201332. doi: 10.1126/scitranslmed.3000544.", "ArticleIdList": ["10.1126/scitranslmed.3000544", "PMC3033690", "20445200"]}, {"Citation": "Cummings M.D., Lindberg J., Lin T.I., de Kock H., Lenz O., Lilja E., Fell\u00e4nder S., Baraznenok V., Nystr\u00f6m S., Nilsson M. Induced-fit binding of the macrocyclic noncovalent inhibitor TMC435 to its HCV NS3/4A protease target. Angew. Chem. Int. Ed. Engl. 2010;49:1652. doi: 10.1002/anie.200906696.", "ArticleIdList": ["10.1002/anie.200906696", "20166108"]}, {"Citation": "Romano P., Ali A., Royer W.E., Schiffer C.A. Drug resistance against HCV NS3/4A protease inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proc. Natl. Acad. Sci. USA. 2010;107:20986. doi: 10.1073/pnas.1006370107.", "ArticleIdList": ["10.1073/pnas.1006370107", "PMC3000259", "21084633"]}, {"Citation": "Tanji H.M., Hirowatari Y., Shimotohno K. Hepatitis C virus polyprotein processin: Kinetic and mutageni analysis of serine proteinase-dependent cleavage. J. Virol. 1994;68:8418. doi: 10.1128/jvi.68.12.8418-8422.1994.", "ArticleIdList": ["10.1128/jvi.68.12.8418-8422.1994", "PMC237315", "7966638"]}, {"Citation": "Beran R.K., Serebrov V., Pyle A.M. The serine protease domain of Hepatitis C viral NS3 activates RNA helicase activity by promoting the binding of RNA substrate. J. Biol. Chem. 2007;282:34913. doi: 10.1074/jbc.M707165200.", "ArticleIdList": ["10.1074/jbc.M707165200", "17921146"]}, {"Citation": "Beran R.K., Pyle A.M. Hepatitis C viral NS3-4A protease activity is enhanced by the NS3 helicase. J. Biol. Chem. 2008;283:29929. doi: 10.1074/jbc.M804065200.", "ArticleIdList": ["10.1074/jbc.M804065200", "PMC2573085", "18723512"]}, {"Citation": "Love R.A., Parge H.E., Wickersham J.A., Hostomsky Z., Habuka N., Moomaw E.W., Adachi T., Hostomska Z. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell. 1996;87:331\u2013342. doi: 10.1016/S0092-8674(00)81350-1.", "ArticleIdList": ["10.1016/S0092-8674(00)81350-1", "8861916"]}, {"Citation": "Molecular Operating Environment (MOE) Chemical Computing Group; Montreal, QC, Canada: 2016.  [(accessed on 16 January 2022)].  version 2016, 08. Available online:  www.chemcomp.com."}, {"Citation": "Satoh S., Tanji Y., Hiikata M., Kimura K., Shimotohno K. The N terminal region of Hepatitis C virus nonstructural protein3 (NS3) is essential for stable complex formation with NS4A. J. Virol. 1995;69:4255. doi: 10.1128/jvi.69.7.4255-4260.1995.", "ArticleIdList": ["10.1128/jvi.69.7.4255-4260.1995", "PMC189163", "7769685"]}, {"Citation": "Chen S., Wu Z., Wang M., Cheng A. Innate immune evasion mediated by flaviviridae non-structural proteins. Viruses. 2017;9:291. doi: 10.3390/v9100291.", "ArticleIdList": ["10.3390/v9100291", "PMC5691642", "28991176"]}, {"Citation": "De Francesco R.A., Urbani M.C., Nardi M.C., Tomei L., Steink\u00fchler C., Tramontano A. A zinc binding site in viral serine proteinases. Biochemistry. 1996;35:13282. doi: 10.1021/bi9616458.", "ArticleIdList": ["10.1021/bi9616458", "8873593"]}, {"Citation": "De Francesco R.A., Pessi A., Steink\u00fchler C. The Hepatitis C virus NS3 proteinase: Structure and function of a zinc containing serine proteinases. Antivir. Ther. 1988;3:99. doi: 10.1177/135965359800303S01.", "ArticleIdList": ["10.1177/135965359800303S01", "10726060"]}, {"Citation": "Han D.S., Hahm B., Rho H.M., Jang S.K. Identification of the protease domain in NS3 of Hepatitis C virus. J. Gen. Virol. 1995;76:985. doi: 10.1099/0022-1317-76-4-985.", "ArticleIdList": ["10.1099/0022-1317-76-4-985", "9049347"]}, {"Citation": "Kakiuchi N., Komoda Y., Hiikata M., Shimotohno K. Cleavage activity of Hepatitis C virus serine proteinase. J. Biochem. 1997;122:749. doi: 10.1093/oxfordjournals.jbchem.a021819.", "ArticleIdList": ["10.1093/oxfordjournals.jbchem.a021819", "9399578"]}, {"Citation": "Melagraki G., Afantitis A. Ligand and structure-based virtual screening strategies for hit-finding and optimization of hepatitis C virus (HCV) inhibitors. Curr. Med. Chem. 2011;18:2612\u20132619. doi: 10.2174/092986711795933759.", "ArticleIdList": ["10.2174/092986711795933759", "21568888"]}, {"Citation": "Barreca M.L., Iraci N., Manfroni G., Cecchetti V. Allosteric inhibition of the hepatitis C virus NS5B polymerase: In silico strategies for drug discovery and development. Future Med. Chem. 2011;3:1027\u20131055. doi: 10.4155/fmc.11.53.", "ArticleIdList": ["10.4155/fmc.11.53", "21707403"]}, {"Citation": "Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development setting. Adv. Drug Deliv. Rev. 2001;46:3\u201326. doi: 10.1016/S0169-409X(00)00129-0.", "ArticleIdList": ["10.1016/S0169-409X(00)00129-0", "11259830"]}, {"Citation": "Lewell X.Q., Judd D.B., Watson S.P., Hann M.M. RECAP\u2014Retrosynthetic combinatorial analysis procedure: A powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J. Chem. Inf. Comput. Sci. 1998;38:511\u2013522. doi: 10.1021/ci970429i.", "ArticleIdList": ["10.1021/ci970429i", "9611787"]}, {"Citation": "Schneider G., Fechner U. Flux (1): A virtual synthesis scheme for fragment-based de novo design. J. Chem. Inf. Model. 2006;46:699\u2013707.", "ArticleIdList": ["16563000"]}, {"Citation": "Weininger D. SMILES 1 introduction and encoding rules. J. Chem. Inf. Comput. 1988;28:31\u201336. doi: 10.1021/ci00057a005.", "ArticleIdList": ["10.1021/ci00057a005"]}, {"Citation": "Labute P. The generalized born/volume integral (GB/VI) implicit solvent model: Estimation of the free energy of hydration using London dispersion instead of atomic surface area. J. Comput. Chem. 2008;29:1693\u20131698. doi: 10.1002/jcc.20933.", "ArticleIdList": ["10.1002/jcc.20933", "18307169"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "12", "Day": "19"}, {"Year": "2023", "Month": "1", "Day": "18"}, {"Year": "2023", "Month": "1", "Day": "19"}, {"Year": "2023", "Month": "2", "Day": "11", "Hour": "1", "Minute": "35"}, {"Year": "2023", "Month": "2", "Day": "12", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "2", "Day": "15", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "1", "Day": "29"}], "PublicationStatus": "epublish", "ArticleIdList": ["36770965", "PMC9918934", "10.3390/molecules28031300", "molecules28031300"]}}], "PubmedBookArticle": []}